| | HPV 16 | HPV 18 | HPV 52 | HPV 58 | Other hrHPVs | Negative | p-value |
|---|
| Age (years) | 37 ± 0.9 | 39 ± 3.6 | 38 ± 0.8 | 39 ± 1.0 | 44 ± 1.2 | 40 ± 1.7 | 0.001*1 |
| Months since diagnosis | 40 ± 5.2 | 38 ± 10.0 | 36 ± 4.4 | 39 ± 5.1 | 37 ± 7.2 | 37 ± 7.0 | 0.95*1 |
| Smoking (%) | 15/55 (27.3) | 3/10 (30.0) | 14/56 (25.0) | 19/56 (28.4) | 16/72 (22.2) | 7/39 (18.0) | 0.57*2 |
| Parity ≥1 (%) | 23/57 (40.3) | 3/10 (30.0) | 23/56 (41.1) | 22/57 (38.6) | 26/74 (35.1) | 15/40 (37.5) | 0.97*2 |
| Steroid use (%) | 0/59 (0.0) | 0/10 (0.0) | 2/57 (3.5) | 2/58 (3.5) | 2/74 (2.7) | 1/36 (2.8) | 0.56*2 |
- Clinical features were summarized according to HPV categorize. HPVs 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 were classified as hrHPVs. Of these, HPV 16, 18, 52, and 58 were categorized separately. hrHPVs other than HPVs 16, 18, 52, and 58 were classified as “other hrHPVs.” Patients who were not infected with any hrHPVs were referred to as “no hrHPVs” patients. Statistical analysis was performed using a Steel-Dwass test (*1) and the Analysis of Variance (*2)
- HPV human papillomavirus
